ATE432926T1 - Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung - Google Patents

Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung

Info

Publication number
ATE432926T1
ATE432926T1 AT05773290T AT05773290T ATE432926T1 AT E432926 T1 ATE432926 T1 AT E432926T1 AT 05773290 T AT05773290 T AT 05773290T AT 05773290 T AT05773290 T AT 05773290T AT E432926 T1 ATE432926 T1 AT E432926T1
Authority
AT
Austria
Prior art keywords
histamine
nitrogen
formula
ring
compounds
Prior art date
Application number
AT05773290T
Other languages
German (de)
English (en)
Inventor
Lisa Beavers
Serge Boulet
Terry Finn
Robert Gadski
William Hornback
Cynthia Jesudason
Richard Pickard
Freddie Stevens
Grant Vaught
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE432926T1 publication Critical patent/ATE432926T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05773290T 2004-07-26 2005-07-14 Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung ATE432926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
ATE432926T1 true ATE432926T1 (de) 2009-06-15

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05773290T ATE432926T1 (de) 2004-07-26 2005-07-14 Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung

Country Status (17)

Country Link
US (1) US7666871B2 (OSRAM)
EP (1) EP1786790B1 (OSRAM)
JP (1) JP4982367B2 (OSRAM)
CN (1) CN1989115B (OSRAM)
AT (1) ATE432926T1 (OSRAM)
AU (1) AU2005275183B2 (OSRAM)
BR (1) BRPI0513777A (OSRAM)
CA (1) CA2575081C (OSRAM)
CY (1) CY1109493T1 (OSRAM)
DE (1) DE602005014786D1 (OSRAM)
DK (1) DK1786790T3 (OSRAM)
ES (1) ES2325865T3 (OSRAM)
MX (1) MX2007001029A (OSRAM)
PL (1) PL1786790T3 (OSRAM)
PT (1) PT1786790E (OSRAM)
SI (1) SI1786790T1 (OSRAM)
WO (1) WO2006019833A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1848428A4 (en) 2005-02-18 2012-04-18 Neurogen Corp THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS
EP1866293A1 (en) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
CA2645731A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
BRPI0711655A2 (pt) * 2006-05-19 2011-11-29 Basf Se composto, processo para preparar compostos, composição, processo para preparar composições, proceeso para combater vegetação indesejada, e, uso do composto
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010533725A (ja) 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐3(h3)受容体としてのアミノアルキルアゾール化合物
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
SG186275A1 (en) 2010-07-06 2013-01-30 Astrazeneca Ab Therapeutic agents 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SG11201505631PA (en) 2013-01-23 2015-08-28 Astrazeneca Ab Chemical compounds
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
PE20180506A1 (es) 2015-06-03 2018-03-09 Bristol Myers Squibb Co Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
IL162834A0 (en) 2002-02-01 2005-11-20 Novo Nordisk As Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
CA2575081A1 (en) 2006-02-23
US20070197604A1 (en) 2007-08-23
EP1786790A1 (en) 2007-05-23
PT1786790E (pt) 2009-08-18
AU2005275183A1 (en) 2006-02-23
EP1786790B1 (en) 2009-06-03
SI1786790T1 (sl) 2009-10-31
CY1109493T1 (el) 2014-08-13
US7666871B2 (en) 2010-02-23
PL1786790T3 (pl) 2009-10-30
AU2005275183B2 (en) 2011-03-17
DE602005014786D1 (de) 2009-07-16
MX2007001029A (es) 2007-04-12
WO2006019833A1 (en) 2006-02-23
DK1786790T3 (da) 2009-07-20
CA2575081C (en) 2013-05-07
BRPI0513777A (pt) 2008-05-13
JP2008507579A (ja) 2008-03-13
JP4982367B2 (ja) 2012-07-25
ES2325865T3 (es) 2009-09-22
CN1989115B (zh) 2012-03-21
CN1989115A (zh) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE432926T1 (de) Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
NZ627750A (en) Carbamate compounds and of making and using same
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
MY142807A (en) Benzimidazole derivative and use thereof.
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
RU2006147307A (ru) Производные 3-карбамоил-2-пиридона
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
TW200716528A (en) Cyclopropanecarboxamide derivatives
EA200970705A1 (ru) Новые фармацевтические композиции
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
ATE530187T1 (de) Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
MX2007005709A (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
CA2417082A1 (en) New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
JP2010513489A5 (OSRAM)
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1786790

Country of ref document: EP